Clinical Observation of Sitagliptin plus Glargine Insulin versus Repaglinide plus Glargine Insulin in the Treatment of Type-2 Diabetes_West China Medical Journal

Authors：

 HUAYan , WUJin-wen , JIANGCheng-xia , LIMei , LIUXin

Department of Endocrinology, the Second People's Hospital of Yibin City, Yibin, Sichuan 644000, P. R. China;

Corresponding?author：

Keywords：

Sitagliptin; Repaglinide; Glargine insulin; Type-2 diabetes mellitus

DOI：

10.7507/1002-0179.20140440

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the efficacy of sitagliptin plus glargine insulin versus repaglinide plus glargine insulin in the treatment of Type-2 diabetes mellitus (T₂DM). Methods A total of 140 T₂DM patients who were inadequately controlled by oral anti-diabetic agents from January 2011 to December 2012 were divided into sitagliptin plus glargine insulin group (observation group) or repaglinide plus glargine insulin group (control group). The duration of treatment was 12 weeks. Fasting blood glucose (FBG), 2h plasma glucose (2hPG), glycated haemoglobin (HbA1c), body max index (BMI) and dose of insulin as well as hypoglycemia events were recorded and analyzed. Results After treatment, FBG, 2hPG, and HbA1c were significantly decreased in both groups (P<0.05). HbA1c targeting rate was 88.3% in the observation group and 87.8% in the control group. Compared with the control group, the observation group used 12.1% less dosage of insulin, and had decreased BMI and low incidence of hypoglycemia. Conclusion Sitagliptin plus glargine insulin can effectively control blood glucose and body weight with low incidence of hypoglycemia and much less insulin dosage under the same HbA1c targeting rate. Sitagliptin plus glargine insulin is a good combination therapy for the treatment of T₂DM.

Citation： HUAYan, WUJin-wen, JIANGCheng-xia, LIMei, LIUXin. Clinical Observation of Sitagliptin plus Glargine Insulin versus Repaglinide plus Glargine Insulin in the Treatment of Type-2 Diabetes. West China Medical Journal, 2014, 29(8): 1429-1431. doi: 10.7507/1002-0179.20140440 Copy

1.	Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and woman in China[J]. N Engl J Med, 2012, 362(2):1090-1101.
2.	馬學毅, 楊明功, 鄧大同, 等. 現代糖尿病診斷治療學[M]. 北京:人民軍醫出版社, 2007:68-197.
3.	馬艷芬, 劉薇, 袁明霞, 等. 胰島素與口服降糖藥對新診斷2型糖尿病患者β細胞功能的影響[J]. 中國糖尿病雜志, 2009, 17(5):349.
4.	周映紅, 黃文龍, 張惠斌, 等. GLP-1受體激動劑及DPP-4抑制劑的研究進展[J]. 中國藥科大學學報, 2008, 39(5):385-391.
5.	Bergman AJ, Cote J, Mase A, et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase (DPP-4) inhibitor dose not affect the pharmacokinetics of simvastatin in humans[J]. Clin Pharmaol Ther, 2005, 79(2):48.
6.	Basu AK, Bandyopadhyay D, Bandyopahyay R. Insulin in type 2 diabetes:promises to keep[J]. J Indian Med Assoc, 2004, 102(1):438-442.
7.	Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus[J]. Clin Ther, 2004, 263(11):889-901.
8.	Gerich J, Becker RH, Zhu R, et al. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glarging[J]. Diabetes Technol Ther, 2006, 8(2):237-243.
9.	潘宇平, 鄭啟東, 陳婉, 等. 西格列汀聯合二甲雙胍治療2型糖尿病臨床觀察[J]. 中國鄉村醫學, 2013, 6(1):21-22.
10.	Nonaka K, kakikawa T, Sato A, et al. Efficacy and safety of sitaglipt in monotherapy in Japanese patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2008, 79(4):291-298.
11.	Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J]. Diabetologia, 2007, 50(3):1148-1155.
12.	陳卓, 張慶文. DPP-4抑制劑研究進展[J]. 上海醫藥, 2013, 7(1):50-54.
13.	曾麗麗, 丁英杰, 宋宏銳, 等. 二肽基肽酶-Ⅳ抑制劑的最新研究進展[J].中國藥物化學雜志, 2009, 19(1):65-70.
14.	Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase Ⅳ(DPPⅣ) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes[J]. Diabetes, 2005, 54(Suppl 1):A134, 541.
15.	Hansen AM, Hansen JB, Car RD, et al. Kir62 dependent high-affinity repaglinide binding to betacell K (ATP) channels[J]. Br J Pharmacol, 2005, 144(4):551-557.
16.	廖二元, 莫朝暉. 內分泌學[M]. 北京:人民衛生出版社, 2007:1395.

1. Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and woman in China[J]. N Engl J Med, 2012, 362(2):1090-1101.
2. 馬學毅, 楊明功, 鄧大同, 等. 現代糖尿病診斷治療學[M]. 北京:人民軍醫出版社, 2007:68-197.
3. 馬艷芬, 劉薇, 袁明霞, 等. 胰島素與口服降糖藥對新診斷2型糖尿病患者β細胞功能的影響[J]. 中國糖尿病雜志, 2009, 17(5):349.
4. 周映紅, 黃文龍, 張惠斌, 等. GLP-1受體激動劑及DPP-4抑制劑的研究進展[J]. 中國藥科大學學報, 2008, 39(5):385-391.
5. Bergman AJ, Cote J, Mase A, et al. Sitagliptin (MK-0431), a selective dipeptidyl-peptidase (DPP-4) inhibitor dose not affect the pharmacokinetics of simvastatin in humans[J]. Clin Pharmaol Ther, 2005, 79(2):48.
6. Basu AK, Bandyopadhyay D, Bandyopahyay R. Insulin in type 2 diabetes:promises to keep[J]. J Indian Med Assoc, 2004, 102(1):438-442.
7. Dailey G. New strategies for basal insulin treatment in type 2 diabetes mellitus[J]. Clin Ther, 2004, 263(11):889-901.
8. Gerich J, Becker RH, Zhu R, et al. Fluctuation of serum basal insulin levels following single and multiple dosing of insulin glarging[J]. Diabetes Technol Ther, 2006, 8(2):237-243.
9. 潘宇平, 鄭啟東, 陳婉, 等. 西格列汀聯合二甲雙胍治療2型糖尿病臨床觀察[J]. 中國鄉村醫學, 2013, 6(1):21-22.
10. Nonaka K, kakikawa T, Sato A, et al. Efficacy and safety of sitaglipt in monotherapy in Japanese patients with type 2 diabetes[J]. Diabetes Res Clin Pract, 2008, 79(4):291-298.
11. Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes[J]. Diabetologia, 2007, 50(3):1148-1155.
12. 陳卓, 張慶文. DPP-4抑制劑研究進展[J]. 上海醫藥, 2013, 7(1):50-54.
13. 曾麗麗, 丁英杰, 宋宏銳, 等. 二肽基肽酶-Ⅳ抑制劑的最新研究進展[J].中國藥物化學雜志, 2009, 19(1):65-70.
14. Herman G, Hanefeld M, Wu M, et al. Effect of MK-0431, a dipeptidyl peptidase Ⅳ(DPPⅣ) inhibitor on glycaemic control after 12 weeks in patients with type 2 diabetes[J]. Diabetes, 2005, 54(Suppl 1):A134, 541.
15. Hansen AM, Hansen JB, Car RD, et al. Kir62 dependent high-affinity repaglinide binding to betacell K (ATP) channels[J]. Br J Pharmacol, 2005, 144(4):551-557.
16. 廖二元, 莫朝暉. 內分泌學[M]. 北京:人民衛生出版社, 2007:1395.

Previous Article
依托城鄉對口支援建立綿陽地區組織化卒中管理模式
Next Article
Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy

West China Medical Journal

Clinical Observation of Sitagliptin plus Glargine Insulin versus Repaglinide plus Glargine Insulin in the Treatment of Type-2 Diabetes

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content